Approaches To Value-Based Drug Cost-Sharing Offered In NPC Report
This article was originally published in The Pink Sheet Daily
National Pharmaceutical Council and the University of Michigan Center for Value-Based Insurance Design propose applying value-based insurance design principles to help reduce cost-sharing for specialty drugs in a report presented at an Institute of Medicine workshop on patient access to cancer drugs.
You may also be interested in...
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.
DeRoyal’s DeBusk urges a focus on rebates, while Brookings' Ginsburg wants a focus on design, not savings per se, as MedPAC discusses restructuring the Part D design to better accommodate current market dynamics. Formal recommendations to Congress may be approved in the spring.
Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.